Internal Medicine News - New indications for once-daily Coreg
The Food and Drug Administration has approved a new application for Coreg CR (carvedilol phosphate) extended-release capsules for the treatment of mild to severe heart failure, the reduction of cardiovascular mortality in patients who have survived the acute phase of myocardial infarction, and hypertension.
Related Results
Trial data added to coreg labelFlamel Technologies Welcomes FDA Approval of COREG CR™Flamel Technologies Welcomes Nationwide Availability of COREG CR™New & approved: Coreg biotronik home monitoring systemGSK unveils more convenient form of Coreg, targets oncology
The drug, the controlled-release formulation of the immediate-release [beta]-blocker Coreg (carvedilol), will be launched in the first quarter of 2007. For more information, call the manufacturer, GlaxoSmithKline, at 888-825-5249.
COPYRIGHT 2007 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
